DGAP-News: STADA Arzneimittel AG / Key word(s): AGM/EGM
STADA AGM 2012: Executive Board expects further growth in Group sales
and earnings - positive outlook until 2014 confirmed
30.05.2012 / 15:14
---------------------------------------------------------------------
At the Annual General Shareholders' Meeting of STADA Arzneimittel AG, which
took place today, on May 30, 2012, in Frankfurt am Main, the Chairman of
the Executive Board, Hartmut Retzlaff, confirmed the outlook for financial
year 2012 in his remarks. The STADA Executive Board therefore expects, from
today's perspective, a further clear increase in Group sales for 2012 with
the inclusion of recent acquisitions. Despite the earnings burdening
one-time special effects from the further implementation of the 'STADA -
build the future' program, the Executive Board expects a very significant
increase in reported net income for 2012 as compared to 2011. The Executive
Board expects continued growth in the key earnings figures adjusted for
one-time special effects in the Group for 2012 and 2013 and also sees, from
today's perspective, the opportunity for an increase in the high
single-digit percent area in EBITDA adjusted for one-time special effects
for 2012. This would mean that record results are once again targeted for
these key figures in 2012.
In his remarks, Retzlaff not only discussed the challenges in financial
year 2011, but also the positive developments, which have led to a further
diversified sales base and optimized cost structure. In addition to
significant sales growth in Russia and Spain, this was due further progress
in the context of the Group-wide cost efficiency program 'STADA - build the
future' as well as numerous acquisitions in the course of the accelerated
acquisitions policy among other things. Overall, the Group recorded - in
the opinion of the Executive Board - positive operational development in
2011 and showed that STADA's sustainable business model proves itself even
when faced with burdening factors, and the Group is nevertheless in the
position to generate significantly positive operating earnings.
At the end of his talk, the Chairman of the Executive Board discussed the
Group's opportunities and risks as well as its success factors. With a view
to the operational strengths and the recently concluded acquisitions,
Retzlaff affirmed the long-term prognosis envisaged for 2014, according to
which Group sales of approximately EUR 2.15 billion, at an adjusted level,
EBITDA of approximately EUR 430 million and net income of approximately EUR
215 million should be reached.
The Annual General Meeting endorsed all proposals of the Executive Board
and Supervisory Board. Thus, a dividend unchanged from the previous year of
EUR 0.37 per STADA common share was approved. The total dividend payments
of EUR 21.8 million thus represent a dividend ratio of approximately 99% of
reported net income. In addition, the Annual General Meeting confirmed the
Executive Board and the Supervisory Board with high approval.
The wording of today's speech of STADA's Chairman of the Executive Board
Hartmut Retzlaff as well as the exact voting results for all items on the
agenda can be found at STADA's website at www.stada.com/agm2012.
Additional information:
STADA Arzneimittel AG / Corporate Communications / StadastraÃe 2-18 / D -
61118 Bad Vilbel /
Tel.: +49(0) 6101 603-113 / Fax: +49(0) 6101 603-506 / E-Mail:
communications@stada.de /
Or visit us in the Internet at www.stada.com.
End of Corporate News
---------------------------------------------------------------------
30.05.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
StadastraÃe 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime
Standard); Freiverkehr in Berlin, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
172098 30.05.2012
DGAP-News: STADA AGM 2012: Executive Board expects further growth in Group sales and earnings - positive outlook until 2014 confirmed
| Source: EQS Group AG